Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic <i>Candida</i> infections in the UK

Abstract

Costs and effects of micafungin compare to those of caspofungin in the treatment of systemic Candida infections in the UK. The results indicate that micafungin is cost-effective compared to caspofungin, although the difference was not found to be significant.